AANEM News Express

AANEM News Express

AANEM Successfully Fought to Protect CNCT Technologists in Illinois and Louisiana

6/8/2018
 
Unprecedented legislation was presented this past session which had the ability to impact how Certified Nerve Conduction Technologists (CNCT) technologists could promote their certification. AANEM worked successfully with lobbyists in both Illinois and Louisiana to amend or stop the bills from passing.

In Louisiana, House Bill 748, in its original form, would have banned use of the term “certification” issued by credentialing bodies unless the certification was related to a licensure requirement (like a board certification for medical doctors). This expansive bill riled up professionals across the spectrum and resulted in the formation of a far-reaching coalition, which AANEM joined. The coalition successfully amended the bill, deleting much of the original language, including the term “certification.”

In Illinois, a bill was introduced that created a registry for neurodiagnostic technologists but limited the registry to only technologists with an ABRET credential; no other “neurodiagnostic technologists” would have been permitted to refer to themselves as neurodiagnostic technologists. AANEM teamed up with ASET – The Neurodiagnostic Society to hire a lobbyist who worked to amend the bill to include other neurodiagnostic credentials, including CNCT. While the bill was never formally amended before the session ended, the bill did not pass. AANEM is hopeful that if the bill returns next year, the amendment will be included in the bill.  

While most state legislative sessions have concluded for the year, AANEM policy staff will continue to monitor statutory and regulatory changes and work to protect the interests of all AANEM members and ABEM certifications. If you have any questions, please contact the AANEM policy staff


View Related News Stories:

  Advocacy


Recent AANEM News

Science News: Muscular and Extramuscular Clinical Features of Patients with Anti-PM/Scl Autoantibodies

It’s Charcot-Marie-Tooth Awareness Month!

AANEM Comments on 2019 Proposed Update to Physician Fee Schedule & QPP

Today is World Duchenne Awareness Day!

Science News: Safety and Efficacy of Eculizumab in Guillain-Barré Syndrome: A Multicentre, Double-blind, Randomised Phase 2 Trial





Advertisement

TPP

Advertisement

ABEM

Advertisement